05 July 2024 | Statements

Unitaid, IAVI, Medicines Patent Pool and Wellcome publish novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries

Unitaid, IAVI, the Medicines Patent Pool, and Wellcome proudly announced the publication of “Novel Approaches to Enable Equitable Access to Monoclonal Antibodies in Low- and Middle-Income Countries” in the medical journal PLOS Global Public Health. A collaborative effort across co-authors from all partner organizations, the article draws on a multistakeholder consultation to address critical barriers and proposes innovative strategies to enable equitable access to monoclonal antibodies (mAbs) in low- and middle-income countries.

Monoclonal antibodies – lab-engineered antibodies that mimic human antibodies in defending against disease – are revolutionizing the management of various non-communicable and autoimmune diseases in high-income countries. Some mAbs have also been approved for infectious diseases, and many others are currently in development. However, due to systemic challenges, access to mAbs in low- and middle-income countries remains very limited.

This publication describes the challenges inhibiting the accessibility of mAbs in low- and middle-income countries, which include prohibitive costs and ill-adapted formulations, insufficient investment in development for mAbs that target infectious diseases, limited production base, complex intellectual property and regulatory environments and inadequate commercial incentives in low- and middle-income country markets. It outlines possible approaches to overcome these challenges across the value chain, including development and manufacturing, licensing and technology transfer, regulatory pathways, demand creation, and approaches specific to diseases facing different market challenges, including case studies of potential trailblazer mAbs to address specific infectious diseases of public health importance for low- and middle-income countries.

The article provides key recommendations for making these powerful tools more accessible and affordable in regions where they could address unmet needs in the global health response and accelerate progress toward global targets. Unitaid and partners remains committed to working with global health agencies, funders, the private sector, and affected communities to enable equitable access to mAbs for infectious diseases in low- and middle-income countries.

Read the full open-access article here: Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries | PLOS Global Public Health


Media contact:

For more information and media requests:

Kyle Wilkinson

Media Officer

wilkinsonk@unitaid.who.int

+41 79 445 17 45

View All News

Featured News

12 July 2024

Call for Expression of Interest (EOI): Strengthening sustainable regional manufacturing of therapeutics for Maternal health, Malaria and HIV programmatic priorities in Africa

Read More

09 July 2024

Unitaid and Jhpiego reach first women with prevention and treatment for life-threatening bleeding as program awarded EUR 5.5 million in additional funding

Read More

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.